Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.
about
Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
P2860
Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cost-effectiveness of pretrans ...... n after liver transplantation.
@en
type
label
Cost-effectiveness of pretrans ...... n after liver transplantation.
@en
prefLabel
Cost-effectiveness of pretrans ...... n after liver transplantation.
@en
P2093
P2860
P50
P356
P1476
Cost-effectiveness of pretrans ...... n after liver transplantation.
@en
P2093
Alessandro Vitale
Antonio Picciotto
Francesca Donato
Gianluca Svegliati Baroni
Liver Transplantation NITp working group
Luca Belli
Maria Grazia Lucà
Nicola Passigato
Pierluigi Toniutto
Tania Marianelli
P2860
P304
P356
10.1111/TRI.12591
P577
2015-04-30T00:00:00Z